


FIGURE 1

1 2 3 4 5 6 7 8



β -actin

II-10

FIGURE 3

Probes:

β -actin

 ∞

16

28

71

IV PV
IV PV
IV PV
IV PV

-285

-185-

FIGURE 4




FIGURE 5A

1 2 3 4 5




FIGURE 5B

1 2 3 4 5




FIGURE 6





FIGURE 7

	Leader -----	
RAT	ATGGGCAGTCCGGTATTTCAGGAGACCTTTCTGCCATCTGTCCACCTACAGCCTGCTCTGGGCCATAG	67
MOU	-----T-----C-----A-T-----G-----	67
HUM	-----GA-----TG-----CT-----T-----G-T-----T-----G-----	55
	 V-like domain -----	
RAT	CAGCAGTAGCGCTGAGCACAGCTCAAGTGGAAGTGGTGACCCAGGATGAAAGAAAGCTGCTGCACAC	134
MOU	-----GC-----	134
HUM	-----G-T-----T-----A-----C-----A-----T-----	122
RAT	AACTGCATCCTTACGCTGTTCTCTAAAAACAACCCAGGAACCCCTTGATTGTGACATGGCAGAAAAAG	201
MOU	-----A-----T-----	201
HUM	-----T-----AAA-C-----GC-----ATG-----G-C-C-----	189
RAT	AAAGCCGTAGGCCCAGAAAACATGGTCACTTACAGCAAAGCCCATGGGGTTGTCATTTCAGCCCACCT	268
MOU	-----GA-----C-----A-----A-C-----TG-----	268
HUM	-----T-A-----C-T-----G-GAA-----G-G-C-----TG-----	256
RAT	ACAAAGACAGGATAAACATCACTGAGCTGGGACTCTTGAACACAAGCATCACCTTCTGGAACACAAC	335
MOU	-----TG-----A-----G-----T-----CA-----	335
HUM	-T-G-----A-----T-CC-----C-A--T--C-----T-TC--	323
RAT	CCTGGATGATGAGGGTTGCTACATGTGTCTCTTCAACATGTTTGGATCTGGGAAGGTCTCTGGGACA	402
MOU	-A-T-GA-----GA-C-----C-----T--CA-----A-A--	402
HUM	-----G-----A-G-T-----T-CC-----T-T-----A-A-G	390
	 C-like domain -----	
RAT	GCTTGCCTTACTCTCTATGTACAGCCCATAGTACACCTTCACTACAACCTATTTTGAAGACCACCTAA	469
MOU	-----C-----	469
HUM	--C-----C-CG-----TC-----A-TC-C-----	457
RAT	ACATCACGTGCTCTGCAACTGCCCCGCCAGCCCCTGCCATCTCCTGGAAGGGCACTGGGTCAGGAAT	536
MOU	-----T-----G-----T-----A-----T-----A-----	536
HUM	-T-----T-----C-----CATGG--T-----T-C-C-----	524
RAT	TGAGAATAGTACTGAGAGTCACTCCCATTCAAATGGGACTACATCTGTCACCAGCATCCTCCGGGTC	603
MOU	-----C-----T-----	603
HUM	---A-----A-T-C-TG-T-CC-----C-G-----T-----ATA--	591
RAT	AAAGACCCCAAACCTCAGGTTGGAAAGGAAGTGATCTGCCAGGTTTTATACTTGGGGAATGTGATTG	670
MOU	-----	670
HUM	-----T-G-A-----G-G-----GC-GC-C-----C-----CC--	658
	 Transmembrane region -----	
RAT	ACTACAAGCAGAGTCTGGACAAAGGATTTTGGTTTTTCAGTCCCACTGCTGCTGAGCATTGTTTCTCT	737
MOU	-----T-----T-----A-----	737
HUM	---TT-----A-CCG-CA-----C-A-----T-G-AT-----A-----C--	725
	 Cytoplasmic region -----	
RAT	GGTAATTCTTCTGGTCTTGATCTCCATCTTATTATACTGGAAACGGCACCGAAATCAGGAGCGGGGT	804
MOU	-----A-----C-----T-----	804
HUM	-----C-C-A-----A-----C-G-----T-----G-----C-A--	792
RAT	GAGTCATCACAGGGGATGCAAAGAATGAAATAA	837
MOU	--A-----	837
HUM	---TG-----AG-T-----A-----C-----	825

[illegible]

- invariant cysteine residues: •• invariant asparagine (N-linked oligosaccharides)

FIGURE 9



CELLS added to C57BL/6 RESPONDER SPLEEN CELLS

FIGURE 10





FIGURE 11



NPC from Flt3 treated mice

FIGURE 12




FIGURE 13





FIGURE 14



NPC cells infused into renal transplant recipients

FIGURE 15






FIGURE 16



Monoclonal antibodies added to culture

FIGURE 17



Monoclonal antibodies added to culture

FIGURE 18A






FIGURE 18B



Effect of anti-OX2 on spontaneous abortions




Day of infusion of anti-OX2

FIGURE 20


Effect of OX2:Fc on spontaneous abortions or renal allograft rejection

CBA with C57BL/6 grafts




3.

2




FGL 2



OX-2

FIGURE 22

EXPRESSION OF OX-2 ON CYTOKERATIN- POSITIVE CELLS (TROPHOBLAST)




TERM PLACENTA
SUCCESSFUL GRAFT



TROPHOBLAST CELL
SUSPENSION





ANTI-CD 9



CD 9- CD 9+

TROPHOBLAST STROMA



EXPRESSION OF OX-2 ON CYTOKERATIN- POSITIVE CELLS (TROPHOBLAST)

